Topic

Mike Hollan is an Editor for Pharm Exec. He can be reached at 

Articles

While patients continue to benefit from increased product launches, the pandemic is still having an impact on caseload.

IQVIA Releases Global Oncology Trend Report for 2022

Szwarcberg discusses challenges in the rare disease drug development space, and how his background is helping him find solutions for patients, specifically with endocrine disorders.

Q&A With Javier Szwarcberg, MD, MPH, CEO of Spruce Biosciences

Autumn Vaupel is chief operating officer for Beeline, and is responsible for the overall customer experience, driving client growth and retention, and managing business operations.

Pandemic workforce trends continue to create challenges for pharma.

Sustaining Pace With Contingent Workers

Senior Advisor to the FoCUS Project and Chief Clinical Officer for Real Endpoints

Upcoming regulatory changes to create new opportunity for specialized offerings.

Aligning Contracting to Solve for Payer Risks Is a Win for Biopharma, Payers, and Patients

President and CEO, The Corporate Citizenship Project

Rise in demand for sustainable practices forces industry to be more proactive.

Why Pharmaceutical Manufacturers Must Navigate Muddy Waters of ESG Requirements

Hill shares her insights on what is needed for a turnaround in talent development.

Q&A With Harvard Business School Professor Linda A. Hill

Vice President of Analytics and Insights Management, Array

New mediums of technology must be utilized correctly to reap full benefits.

If Content Is King, Context Is the Power Behind the Throne

New regulations set stage for updated ESG considerations.

Biopharma and ESG: Key Strategies for Companies, Meaningful Changes to Communities

Managing director, pharmaceuticals and biotechnology, North America, in WittKieffer’s global life sciences practice

New C-Suite position emerges for more emphasis on patient centricity.

The Role and Recruitment of the Chief Patient Officer

From exposing disparities in care to guiding better patient outcomes to helping reign in the costs of care, the use of real-world data (RWD) in oncology can have far-reaching effects. Here’s how one RWD company exec is using her experience to help drive that change.

Industry Trends